Skip to main content

Table 2 Description of liver dysfunction between non-severe and severe among included studies

From: A meta-analysis of the impact of COVID-19 on liver dysfunction

Study, year

Setting

Country

Sample (non-severe/severe)

Age (non-severe/severe)

Chronic liver disease (non-severe/severe)

ALT (non-severe/severe)

AST (non-severe/severe)

TBIL. (non-severe/severe)

Female

NOS

Chen guang

et al. [17], 2020a

Isolation ward

China

10/11

52.0(42.8–56.0)/61.0 (56.5–66.0)

NA

16.0 (13.3–21.8)/42.0 (32.5–50.0)

24.0(21.5–26.5)/47.0 (28.0–74.5)

7.8 (6.4–9.5)/8.8 (7.9–10.5)

1/3

7

Zheng et a. [18], 2020

Isolation ward

China

131/30

40 (31–51)/57 (46.5–66)

4/0

19.3 (14.6–17.8)/23.9 (17.6–35.3)

23.4 (19.0–28.8)/31.6 (25.9–49.36)

10.7 (8.18–15.3)/12.7 (9.2–16.9)

65/16

7

Wan et al. [11], 2020

Isolation ward

China

95/40

44(33–49)/56(52–73)

1/1

21.7(14.8–36.9)/26.6(14.5–33.3)

22.4(16.9–30.5)/33.6(25.7–44.2)

8.6(5.6–14)/9.8(7.8–15.6)

43/19

8

Zhang et al. [19], 2020b

Isolation ward

China

84/31

43.96 ± 14.84/64.58 ± 13.26

3/2 (Hepatitis B)

21.22 ± 12.67/37.87 ± 32.17

24.39 ± 9.79/38.87 ± 22.55

10.27 ± 4.26/14.12 ± 6.37

55/11

7

Guan et al. [20], 2020c

Isolation ward

China

926/173

45.0(34.0–57.0)/52.0 (40.0–65.0)

22/1 (Hepatitis B)

120/606 vs 38/135

112/615 vs 56/142

59/594 vs 17/128

386/73

8

Ji et al. [21], 2020

Isolation ward

China

163/39

42.9 (32.6 -

51.8)/55.1 (43.7 -71.8)

42/34 (NAFLD)

5/2 (HBsAg)

82/163 vs 19/39

24/163 vs 10/39

13/163 vs 4/39

77/12

7

Cai et al. [8]. 2020d

Isolation ward

China

233/85 (A)

47/43 (B)

NA

78/60 (A)

28/41 (B)

41 (23–65)/67 (47–100) (A)

84 (42–136)/96 (63–159) (B)

34(27–45)/58(41–93) (A)

45(29–81)/80(56–145) (B)

19 (13–26)/22 (18–28) (A)

22 (15–41)/25 (19–32) (B)

NA

7

Li et al. [10], 2020e

Isolation ward

China

279/269

56 (44–66)/65 (54–72)

2/2

61/275 vs 64/266

64/275 vs 115/265

7/275 vs 17/266

153/116

7

  1. Data expressed by mean ± SD, median (IQR) or n/N. IQR = interquartile range. ALT: alanine aminotransferase (> 41 U/L). AST: aspartate aminotransferase (> 40 U/L). TBIL: total bilirubin (> 21 μmol/L). NAFLD: non-alcoholic fatty liver diseases. HBsAg: Hepatitis B virus surface antigen positivity
  2. aPatients based on AST > 40U/L
  3. bPatients based on ALT > 50U/L
  4. cPatients based on TBIL > 17.1 μmol/L
  5. dPatients based on abnormal liver test (Group A) and liver injury (Group B)
  6. eComplication liver dysfunction included 44 non-severe and 62 severe patients